Henan Lingrui Pharmaceutical Co., Ltd. (600285.SH) plans to distribute a dividend of 0.8 yuan per share in 2023, with ex-rights and ex-dividends on June 20th.
Henan Lingrui Pharmaceutical (600285.SH) announced that the company's annual profit distribution plan for 2023 is to distribute RMB...per share.
Henan Lingrui Pharmaceutical Leads Three Key Dividend Stocks In China
Some directors and supervisors of Ling Rui Pharmaceutical (600285.SH) completed a shareholding reduction of 1861,000 shares
Ling Rui Pharmaceutical (600285.SH) announced that company director Wu Xizhen and supervisor Li Jin reduced their holdings of the company by a total of 18...
Ling Rui Pharmaceutical (600285.SH): After implementing the holdings reduction, Xinrui Investment reduced its holdings by 1.92% of the company's shares
Gelonghui, May 14, 丨 Ling Rui Pharmaceutical (600285.SH) announced that recently, the company received a “Notice of Shareholding Reduction Results” from Xinrui Investment. As of May 14, 2024, Xinrui Investment had reduced its holdings of the company's shares by 10.867 million shares through bulk transactions, accounting for 1.92% of the company's total share capital before the implementation of the holdings reduction plan. The implementation of this holdings reduction plan was completed.
Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug
Chinese drug regulator National Medical Products Administration granted a drug registration certificate to Henan Lingrui Pharmaceutical (SHA:600285) for its metformin hydrochloride extended-release ta
Express News | Ling Rui Pharmaceutical: Metformin Hydrochloride Extended-Release Tablets Obtain Drug Registration Certificate
Changes in A-shares | Shareholders plan to reduce their holdings at a high level, Ling Rui Pharmaceutical fell more than 6% and reached a record high yesterday
Gelonghui, May 8 | Yesterday's record high Ling Rui Pharmaceutical (600285.SH) fell by more than 6% and is now reported at 24.9 yuan, with a total market value of 14.1 billion yuan. According to the news, shareholder Emerging Investments plans to reduce its shareholding by no more than 1.92%. Yesterday, the company was sold 972,700 shares by foreign investors, and Land Stock Connect currently holds 9.8192 million shares of Ling Rui Pharmaceutical.
Henan Lingrui Pharmaceutical Co., Ltd.'s (SHSE:600285) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) shares have continued their recent momentum with a 27% gain in the last month alone. Looking back a bit further, it's encouraging to see the sto
Express News | Ling Rui Pharmaceutical: Xinrui Investment plans to reduce its shareholding by no more than 1.92%
Ling Rui Pharmaceutical (600285): Increased dividend rate, performance exceeded expectations
Incident: Ling Rui Pharmaceutical released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 3.311 billion yuan (+10.31% year-on-year) and net profit of 568 million yuan to mother (+22.0 million yuan year over year)
Express News | Ling Rui Pharmaceutical: Net operating cash flow fell 44.91% year-on-year in the first quarter
Is Henan Lingrui Pharmaceutical (SHSE:600285) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe
Open Source Securities released a research report on April 26 stating that it gave Ling Rui Pharmaceutical (600285.SH) a purchase rating. The main reasons for the rating include: 1) impressive revenue growth rate for patch, tablet and capsule products, an
Open Source Securities released a research report on April 26 stating that it gave Ling Rui Pharmaceutical (600285.SH) a purchase rating. The main reasons for the rating include: 1) impressive revenue growth rate for patch, tablet and capsule products, and a further increase in gross margin; 2) strengthening brand building to create new potential, and channel innovation to improve marketing efficiency. (Mainichi Keizai Shimbun)
The Chinese medicine sector fluctuated and rebounded. Ling Rui Pharmaceutical surged 8% to a new high, Tongrentang raised 4% in the short term, and Shouxiangu, Furui shares, and Kunming Pharmaceutical Group had the highest gains.
The Chinese medicine sector fluctuated and rebounded. Ling Rui Pharmaceutical surged 8% to a new high, Tongrentang raised 4% in the short term, and Shouxiangu, Furui shares, and Kunming Pharmaceutical Group had the highest gains.
Express News | Pension appeared as the top ten tradable shareholders of 172 individual stocks in the fourth quarter
Ling Rui Pharmaceutical (600285.SH): Net profit of 190 million yuan in the first quarter increased by 31.98% year-on-year
On April 25, Gelonghui Pharmaceutical (600285.SH) released its first quarter report. Operating revenue was 909 million yuan, up 15.27% year on year, net profit of 190 million yuan, up 31.98% year on year, after deducting non-net profit of 181 million yuan, up 31.55% year on year, with basic earnings of 0.340 yuan per share.
Henan Lingrui Pharma Registers Chewable Asthma Drug in China
Henan Lingrui Pharmaceutical (SHA:600285) received a drug registration certificate from China's National Medical Products Administration (NMPA) for Montelukast, according to a Friday filing on the Sha
Ling Rui Pharmaceutical (600285.SH) received the drug registration certificate for montelukast sodium chewable tablets
Ling Rui Pharmaceutical (600285.SH) issued an announcement. The company recently received approval and issuance from the State Drug Administration...
Express News | Donghai Securities: Focus on investment opportunities in sectors such as pharmacy chains and blood products
Henan Lingrui Pharmaceutical (SHSE:600285) Stock Performs Better Than Its Underlying Earnings Growth Over Last Three Years
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But in contrast you can make much more than 100% if the company does wel
No Data